Moleculin Biotech, Inc. (MBRX) Financial Ratios
11 years of historical data (2015–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
1.97
↑+259% vs avg
5yr avg: 0.55
30Y Low0.0·High2.6
ROE
↓
-319.8%
↑-163% vs avg
5yr avg: -121.8%
30Y Low-320%·High-33%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.4·High0.4
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MBRX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Moleculin Biotech, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $29M | $39M | $234124 | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $896314 |
| Enterprise Value | $21M | $31M | $-3565876 | $-21958171 | $-41481180 | $-68744435 | $-13012466 | $-8865630 | $-6056383 | $-6332448 | $-3814490 |
| P/E Ratio → | -0.09 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 1.97 | 2.61 | 0.04 | 0.04 | 0.02 | 0.03 | 0.11 | 0.10 | 0.08 | 0.08 | 0.06 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MBRX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MBRX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -319.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -319.8% | -319.8% | -135.8% | -76.1% | -44.3% | -32.8% | -103.7% | -88.5% | -75.7% | -61.1% | -55.2% |
| ROA | -171.9% | -171.9% | -78.9% | -62.3% | -41.0% | -28.1% | -63.8% | -58.9% | -60.8% | -54.7% | -47.8% |
| ROIC | -441.5% | -441.5% | -757.4% | -352.9% | -259.0% | -306.5% | -360.8% | -212.8% | -136.2% | -66.0% | -58.7% |
| ROCE | -187.1% | -187.1% | -124.0% | -70.5% | -46.1% | -43.0% | -82.4% | -93.8% | -91.1% | -53.6% | -54.3% |
MBRX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $9M exceeds total debt of $222000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.08 | 0.02 | 0.01 | 0.00 | 0.02 | 0.02 | — | — | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.58 | -0.64 | -0.88 | -0.82 | -0.90 | -0.83 | -0.67 | -0.50 | -0.45 | -0.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | -89.86 |
Net cash position: cash ($9M) exceeds total debt ($222000)
MBRX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.41x means Moleculin Biotech, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.86x to 1.41x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 | 3.78 | 2.06 | 3.75 | 3.88 |
| Quick Ratio | 1.41 | 1.41 | 0.97 | 3.86 | 9.46 | 20.02 | 5.89 | 3.78 | 2.06 | 3.75 | 3.88 |
| Cash Ratio | 1.30 | 1.30 | 0.80 | 3.46 | 8.95 | 19.58 | 5.20 | 3.01 | 1.84 | 3.48 | 3.72 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
MBRX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Moleculin Biotech, Inc. returns 0.4% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.4% | 0.3% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.4% | 0.3% | 0.0% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $12M | $137720 | $79024 | $76278 | $71669 | $26255 | $18098 | $11513 | $8253 | $4368 |
Peer Comparison
Compare MBRX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MBRXYou | $29M | -0.1 | — | — | — | — | -319.8% | -441.5% | — |
 SNDX | $2B | -6.2 | — | — | 96.0% | -158.4% | -161.8% | -54.2% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 AGIO | $2B | -3.9 | — | — | 78.7% | -873.9% | -30.2% | -26.3% | — |
 TPVG | $243M | 4.9 | 9.1 | — | 83.5% | 77.9% | 14.1% | 7.2% | 6.2 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 ALDX | $104M | -1.8 | — | — | — | — | -58.5% | -369.4% | — |
 CASI | $2M | -0.1 | — | — | 39.1% | -138.8% | -301.8% | -153.0% | — |
 CRIS | $76M | -1.0 | — | — | 99.5% | -348.4% | -138.8% | — | — |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 11 years · Updated daily
See MBRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MBRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MBRX vs SNDX
Side-by-side business, growth, and profitability comparison vs Syndax Pharmaceuticals, Inc..
Start ComparisonMBRX — Frequently Asked Questions
Quick answers to the most common questions about buying MBRX stock.
What is Moleculin Biotech, Inc.'s P/E ratio?
Moleculin Biotech, Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
What is Moleculin Biotech, Inc.'s ROE?
Moleculin Biotech, Inc.'s return on equity (ROE) is -319.8%. The historical average is -99.3%.
Is MBRX stock overvalued?
Based on historical data, Moleculin Biotech, Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is Moleculin Biotech, Inc.'s dividend yield?
Moleculin Biotech, Inc.'s current dividend yield is 0.35%.